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Here we present a six-session laboratory exercise designed to introduce students to 
standard biochemical techniques in the context of investigating a high impact 
research topic, acquired resistance to the cancer drug Gleevec. Students express a 
Gleevec-resistant mutant of the Abelson (Abl) tyrosine kinase domain, the active 
domain of an oncogenic protein implicated in chronic myelogenous leukemia 
(CML), and investigate the kinase activity of wild type and mutant enzyme in the 
presence of two cancer drugs. Techniques covered include protein expression, 
purification, and gel analysis, kinase activity assays, and protein structure viewing. 
The exercises provide students with a hands-on understanding of the impact of 
biochemistry on human health, and demonstrate their potential as the next 
generation of investigators.  
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Bcr-Abl is an oncogenic fusion protein that results from a chromosomal 
abnormality. The Bcr-Abl protein contains the tyrosine kinase domain of the Abl protein, 
but lacks the residues responsible for kinase auto-inhibition [1]. Bcr-Abl is therefore a 
constitutively active kinase, which means the default enzyme setting is “on”. The 
unregulated kinase activity of Bcr-Abl leads to chronic myelogenous leukemia (CML), a 
cancer that represents ~ 15% of all adult leukemias. High throughput screening and the 
“rational design” of small molecule inhibitors for Bcr-Abl culminated in the development 
of the drug Gleevec (also called imatinib or STI-576), which shows excellent efficacy 
against CML and was approved by the FDA in 2001 [2]. Gleevec has been called a magic 
bullet cure for cancer [3] and was the first example of a small molecule tyrosine kinase 
inhibitor to treat human disease. Gleevec inhibits Bcr-Abl by binding in the ATP-binding 
site and in a nearby hydrophobic pocket in the inactive conformation of the Abl kinase 
domain (Figure 1) [2, 4].  
Unfortunately, a small percentage of CML patients do not respond to Gleevec 
treatment, and other patients who initially respond to treatment eventually develop 
Gleevec resistance. The majority of these cases can be linked to a single amino acid point 
mutation in the Abl kinase domain of Bcr-Abl, and over 50 different mutations that 
confer Gleevec resistance have been identified [1]. One of the more common mutations is 
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H396P [5], which destabilizes the inactive (Gleevec-binding) form of the Abl kinase 
domain [1].  
In this laboratory exercise students express and purify the H396P mutant of the 
Abl kinase domain (human Abl 1a residues 229-511). Students perform coupled 
phosphorylation assays to determine the specific activity and extent of inhibition of the 
wild type and H396P Abl kinase domain, respectively, in the presence of Gleevec and in 
the presence of Dasatinib, a second generation drug that was FDA approved in 2006 [6]. 
Students use a molecular viewing program to analyze the structural basis of inhibitor 
binding and mechanisms of drug resistance. Structure viewing also enables students to 
explore a second Gleevec-resistant Bcr-Abl mutant, the T315I mutant, which confers 
resistance in a completely different way than H396P and for which there are currently no 
approved drug inhibitors. 
The six sessions presented below are part of a ten-week laboratory course in the 
Department of Chemistry at the Massachusetts Institute of Technology, developed in 
2007 as the biochemistry component of a curriculum redesign focused on “research-
inspired” laboratory modules. The course, which includes a total of fifteen two- to four-
hour laboratory sessions, is offered to sophomores, juniors and seniors who have 
completed a prerequisite biochemistry lecture course. Additional activities in the lab 
course, which are not described here, include DNA digestion and site directed 
mutagenesis, in which students design primers to create the DNA for another Gleevec-
resistant Abl-mutant of their choice. These additional exercises are interwoven with the 
sessions presented here. The complete 15-session laboratory course (MIT course 5.36), 
including six background and technique lectures, is freely available on the web via MIT 
OpenCourseWare [7].  
 
LABORATORY STRUCTURE BY SESSION 
 (~ four hours each) 
Sessions 1 and 2: Co-expression of the H396P Abl kinase domain with Yop phosphatase. 
Preparation of protein purification and kinase assay buffers.  
Session 3: Cell lysis and purification of the H396P Abl kinase domain.  
Session 4: SDS-PAGE gel analysis of the purified H396P Abl kinase domain, protein 
concentration, and quantification using a protein concentration assay based on the 
Bradford method. 
Session 5: Kinase activity assays of the (commercially-available) wild type and H396P 
mutant Abl kinase domains in the presence and absence of small molecule Abl inhibitors 
(and approved CML cancer drugs) Gleevec and Dasatinib. 
Session 6: Analysis of the mechanism of Abl inhibition and the effect of other Abl 
mutants of inhibitor binding using a protein structure-viewing program. 
 
Detailed student and instructor manuals and supply / equipment lists are provided in 
supplemental materials. 
 
Co-expression of the H396P Abl kinase domain with Yop phosphatase 
(Sessions 1 and 2) 
 Until recently, overexpression of the Abl kinase domain was not practical for a 
basic undergraduate laboratory. Kinase activity can be toxic to bacterial cells, and thus 
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there were no reported methods for isolating mg quantities of the Abl kinase domain from 
E. coli. Fortunately, in 2005, researchers overcame this limitation by co-expression of the 
kinase domain with a protein phosphatase, YopH [8]. The H396P Abl mutant expression 
and purification used here is modified from published protocols to fit into four-hour 
laboratory sessions. In lab Session 1, students are provided with BL21-DE3 expression 
cells co-transformed with two expression vectors; a kanamycin-resistant vector encoding 
a hexahistidine-tagged H396P Abl kinase domain and a streptomycin-resistant vector 
encoding the YopH phosphatase. Students prepare LB media with both kan and strep 
antibiotics with an emphasis on establishing sterile techniques. Students grow 20-mL 
overnight starter cultures, then inoculate 500 mL of LB/kan/strep and grow the culture to 
midlog phase at 37 °C (approximately 3 hours). The culture is then transferred to an 
unheated shaker, induced with 0.2 mM IPTG and grown at room temperature overnight. 
Cells are harvested by centrifugation, and the resulting cell pellet is frozen at -20 °C until 
Session 3.  
 
Preparation of protein purification and kinase assay buffers  
(Sessions 1 and 2) 
 An essential component of any biochemistry education is a proficiency in 
calculating and preparing buffers. During Sessions 1 and 2, students calculate the needed 
quantities of components, and prepare and adjust the pH of buffers used in Sessions 3 
through 5. These buffers include Ni-NTA binding, washing, and eluting buffers, TBS, gel 
pouring and electrophoresis buffers, and Tris-based buffers for running the kinase activity 
assays. Students also prepare a stock solution of BSA, which is used in Session 4 for 
protein quantification. 
 
Affinity-tag purification of the H396P Abl kinase domain 
(Session 3) 
 The H396P Abl kinase domain is isolated from cellular proteins and the YopH 
phosphatase via its amino-terminal hexahistidine tag. Ni-NTA resin is one of the least 
expensive affinity purification resins and can be regenerated and reused, making 
hexahistidine affinity purification an economic choice for an undergraduate lab. For cell 
lysis, the pellet is thawed, and then resuspended in 20 mL of B-PER detergent in the 
presence of a protease inhibitor cocktail. The suspension is agitated for 10 min at 4 °C 
and then subjected to centrifugation. The soluble fraction is incubated with 1 mL of Ni-
NTA resin in ~ 50 mL of binding buffer (50 mM Tris, 300 mM NaCl, pH 7.8) for 20 
minutes, and the resin slurry is poured into a plastic column and then washed with 30 mL 
of washing buffer (binding buffer plus 30 mM imidazole). The protein is eluted with 1.2 
mL aliquots of elution buffer (binding buffer plus 200 mM imidazole). Students measure 
the absorbance of each fraction at 280 nm, and combine the fractions with the highest 
absorbance, indicating the highest protein concentrations. These fractions are dialyzed 
into TBS buffer (200 mM Tris, 1.4 M NaCl, pH 7.5) to remove the imidazole. 
 
SDS-PAGE gel analysis of H396P Abl, and protein concentration and quantification 
Session 4 
 Students pour an SDS-PAGE gel and prepare protein elution samples for gel 
analysis. The gel is run at 200 V for one hour, stained with Coomasie blue dye for 10 to 
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25 minutes, and then destained. Students take a picture of their gel for their lab report, as 
shown in Figure 2. The Abl kinase domain appears as a band at approximately 33 kDa. 
YopH phosphatase sticks somewhat to Ni-NTA resin despite having no hexahistidine tag, 
so a band for YopH can be seen in concentrated gel fractions. Published protocols use 
anion exchange to achieve higher Abl purity, but the single Ni-NTA purification is 
suitable for the needs of this lab.  
 Students concentrate the protein to approximately 0.5 mL using centrifugal 
concentrators and use a quantification assay based on the Bradford method to determine 
the protein concentration of the H396P Abl kinase domain after purification and dialysis. 
Final protein concentrations vary widely in the hands of students, ranging from 2 to 20 
mg/mL. Protein is stored at 4 °C until Session 5. 
 
Kinase activity assays of the wild type and H396P mutant kinase domains 
Session 5 
 Students perform coupled phosphorylation assays to determine the specific 
activity of the  (commercially available) wild type Abl kinase domain and the (student-
expressed) H396P mutant kinase domain 1) in the absence of an inhibitor 2) in the 
presence of the drug Gleevec, and 3) in the presence of the drug Dasatinib. The kinase 
activity of the wild type and H396P Abl kinase domains is monitored via an assay that 
“couples” the kinase-mediated conversion of ATP to ADP with the oxidation of NADH 
to NAD+ (Figure 3), which can be detected by a decrease in NADH absorbance at 340 
nm. The assay is ideal for an undergraduate setting, since, unlike other common strategies 
for monitoring kinase activity, it does not require radioactive material or a fluorometer. 
 For each inhibitor-free assay, a 120 µL reaction is set up in an eppendorf tube 
with 3 µL (0.03 µg) of wild type or 10 µL (2 to 20 µg) of mutant Abl kinase domain, 100 
mM Tris, pH 7.5, 10 mM MgCl2, 2 mM ATP, 155 µM NADH, 1 mM PEP, 74 U/mL 
pyruvate kinase (PK), and 104 U/mL lactate dehyrogenase (LDH). The solution is gently 
mixed with tapping, and then transferred to a quartz cuvette with a 100-µL window. To 
determine background ATPase activity, which is later subtracted from the slope of the 
reaction, the absorbance at 340 nm is recorded for two to four minutes. The substrate 
peptide (EAIYAAPFAKKK) is then added to a final concentration of 1 mM to start the 
reaction, and the decrease in absorbance at 340 nm is monitored for five to ten minutes. 
For reactions in the presence of an inhibitor, 1 µM of Gleevec or Dasatinib is added to 
the reaction mixture. Note that the reactions can be run by experienced hands at a final 
volume of 100 µL, but that in the hands of students, a 120 µL reaction leaves room for 
imperfect transfer and results in far more consistent measurements with a 100 µL cuvette.  
 Normalized student assay results for the six reactions (wild-type Abl with no 
inhibitor, wild type Abl with Gleevec, wild type Abl with Dasatinib, H396P Abl with no 
inhibitor, H396P Abl with Gleevec, and H396P Abl with Dasatinib) are shown in Figure 
4. The corresponding specific activities in the absence and presence of inhibitors for the 
wild type and the H396P mutant Abl kinase domains are presented in Table 1. Detailed 
instructions for calculating specific activities are provided in the supplemental materials 
on pg. 18 of the student manual. In the discussion section of their laboratory reports, 
students interpret the assay findings, which indicate that 1 µM Gleevec inhibits the wild 
type enzyme, with a 66% decrease in specific activity, but does not significantly inhibit 
the H396P mutant, with only a 17% decrease in specific activity (percentages calculated 
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from the student data shown). In contrast, 1 µM Dasatinib completely or nearly 
completely inhibits both the wild type and the H396P mutant Abl kinase domains.  
 
An important note on data analysis: In this laboratory students compare the specific 
activity in the absence and presence of inhibitors for both the wild type and the H396P 
mutant Abl kinase domains to determine the effectiveness of each inhibitor on the wild 
type and the mutant protein. It is NOT valid to compare absolute values of specific 
activities between the wt and mutant. The activity of the mutant Abl kinase domain is 
significantly lower than the commercially available wild type protein because of 
differences in purity, the presence of the hexahistidine tag on the mutant, and the pre-
activation by phosphorylation of the commercial wild type enzyme. In addition, a 2006 
study demonstrated that the H396P mutation itself results in decreased in vitro kinase 
activity compared to the wild type [9].   
 
Protein Structure Viewing 
Session 6 
 In the final session students complete a structure viewing exercise using the (free) 
molecular viewing program PyMol [10] to analyze the structural basis of Abl inhibition 
by Gleevec and Dasatinib. The structure viewing exercise is available in the supplemental 
materials (pages 21-27 of the student manual) and provides basic PyMol manipulation 
instructions and series of questions that lead students to explore Abl structures (PBD IDs: 
1IEP, 2GQG, 2F4J), compare binding mechanisms of Gleevec and Dasatinib, and make 
conclusions about modes of drug-resistance. A general understanding of kinase structure 
is helpful for the more complex questions on the worksheet. A one-page published primer 
on kinase inhibition provides a succinct overview [11], and the lecture slides and notes on 
conserved and variable features of kinase domains, which can be found as Lecture 4 on 
the course 5.36 webpage [7], provide a more in-depth lesson. 
 
 A number of extensions can be added to facilitate more student design into this 
laboratory experience. For example, for the MIT course in which these exercises are 
included, students select a second Abl mutant of their choice from the over 50 point 
mutations implicated in CML, and they design primers to create the DNA for that mutant. 
Students are asked to justify their mutant selection based on information from an 
assigned review article [1] and/or published crystal structures. Another opportunity for 
student design is in the kinase assays. Extensions could include planning control 
experiments to test assay assumptions, using other kinases to probe drug selectivity, or 
designing experiments with additional inhibitors. Depending on course resources and 
time constraints, these activities could be carried out in the laboratory or simply written 
up by the students as proposals within their laboratory reports.  
 
Laboratory report 
Student laboratory reports include:  
• an introduction, which briefly describes the purpose of the research and provides 
background information based on an assigned review paper on Bcr-Abl inhibitors [1] 
• a methods section describing the lab work in a concise format 
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• experimental results and data analysis, including a picture of the protein gel, BSA 
assay results, graphs of all kinase assays, a table including the slope, enzyme amount, 
and specific activity for each kinase assay (such as Table 1), and a sample calculation 
of specific activity 
• a discussion section. In the discussion, students compare specific activity results to 
make conclusions about how effective each drug is in inhibiting the wild type and the 
H396P mutant Abl kinase domains. Students are encouraged to incorporate information 
from the crystal structures viewed in Session 6 to explain their data. For example, the 
lab data shows that Dasatinib effectively inhibits the H396P mutant, but that Gleevec 
does not. Through the structure viewing exercise students determine that Dasatinib 
binds the active form of Abl, while Gleevec binds the inactive form. Since the H396P 
mutant destabilizes the inactive form of Abl, the crystal structures support the observed 
data. Students also submit the completed structure viewing worksheet in the appendix 
of their laboratory report. 
 
Student-reported gains 
 Multi-session laboratory exercises with a unifying research problem enable 
students to develop and apply basic research skills in an inspiring context, as 
demonstrated in a number of project-based laboratories in colleges across the country 
[12-15]. Following implementation of the Gleevec lab exercises at MIT in the spring 
semesters of 2008 and 2009 as part of a biochemistry laboratory course, students reported 
significant gains in the following skills: protein expression and purification, enzymatic 
assays, and protein structure viewing, reporting a proficiency (on a 7-point scale) increase 
from 3.0 prior to the course to 5.3 following the course, averaged over all skills (Table 2, 
N = 44, a 74% response rate). The students’ self reported gains were qualitatively 
confirmed by TA and instructor observations in the lab and based on the high quality of 
the student laboratory reports. Students also responded with extremely high ratings of 
agreement with the following additional statements on the 2009 survey (N = 16, a 64% 
response rate): “As a result [of this lab] I have a better understanding of how chemistry 
research can have a direct impact of human health and medicine” (6.2/7) and “I found 
that learning biochemistry techniques in the context of an overarching research project 
made learning more interesting” (6.0/7). Students disagreed with the statement that “I 
would have preferred to have each laboratory technique introduced separately, instead of 
as part of an ongoing research project” (2.6/7). In addition, the 2009 course rating on 
standard MIT course evaluations was a 6.0/7 (N = 25, a 100% response rate) an excellent 
rating for any course, and an extremely high rating for a lab course. For reference, the 
corresponding lab had an average rating of 4.2 out of 7 over the five years prior to being 
replaced by our course. Taken together, the survey responses suggest that students made 
significant gains in laboratory skills during the course and that the topic of investigating 
Gleevec resistance provides an exciting format for learning lab techniques and makes a 
clear connection between research and human health.  
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Table 1. Specific activities and the experimental data for calculating specific activities 
for each of the student-run 120 µL reactions shown in Figure 4. See supplemental 
information (page 18 of the student manual) for specific activity calculation details. 
 ⏐slope ⏐ R2 background 
⏐slope ⏐ 
Final  
⏐slope ⏐ 
Enzyme 
amount 
(µg) 
specific 
activity* 
(U/mg) 
wt Abl, no inhibitor 0.0052 0.948 0.0003 0.0049 0.030 3.2 
wt Abl, 1 µM Gleevec 0.0027 0.914 0.001 0.0017 0.030 1.1 
wt Abl, 1 µM Dasatinib 0.0002 0.064 0.001 - 0.030 > 0 
H396P Abl, no inhibitor 0.0089 0.983 0.0021 0.0068 3.8 0.035 
H396P Abl, 1 µM Gleevec 0.0078 0.988 0.0021 0.0057 3.8 0.029 
H396P Abl, 1 µM Dasatinib 0.0017 0.745 0.0013 0.0004 3.8 0.002 
 
 
Table 2. Student-reported proficiency with the basic biochemistry techniques prior to and 
following the completion of the lab exercises. All items are on a 7-point scale from 1 (not 
at all proficient) to 7 (very proficient). Reported means are aggregated across student 
responses from 2008 and 2009. N = 44 (out of 60 students total: a 73% response rate) 
 Prior to lab Following lab completion 
Protein expression and purification 2.9 5.3 
Enzymatic assays 2.9 5.3 
Protein structure viewing 3.3 5.4 
 
 
Fig. 1. Gleevec (green) bound to the 
inactive conformation of the Abl kinase 
domain (purple). PDB ID: 1IEP [4].  
 
 
 
Fig. 2. Student SDS-PAGE gel of H396P 
Abl kinase domain. Lane 1: molecular 
weight ladder, lane 2: pre-induction 
sample, lane 3: crude protein solution, 
lanes 4 – 10: elution samples. 
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Fig. 3. Coupled phosphorylation assay. Through two additional enzymatic reactions 
(catalyzed by pyruvate kinase (PK) and lactate dehydrogenase (LDH)) the Abl kinase 
activity is coupled to the conversion of NADH to NAD+, which can be monitored by a 
decrease in NADH absorbance at 340 nm.  
 
 
 
Fig. 4. Results of coupled phosphorylation assays (student data). Change in absorption 
over time normalized to an absorbance of 1.0 at t = 0 for A) the wild type Abl kinase 
domain and B) the H396 mutant Abl kinase domain in the presence of no inhibitors (blue 
diamonds), 1 µM Gleevec (green squares), and 1 µM Dasatinib (purple triangles).  
 
 
Fig. 1. Gleevec (green) bound to the inactive conformation of the Abl kinase domain 
(purple). Asp381, Gly382 and Phe383 are shown in ball-and-stick form to highlight the 
“DGF-out” conformation, characteristic of the inactive form of kinases. Thr315, a residue 
explored in the structure viewing exercise in Session 6, is also shown in ball and stick 
form. PDB ID: 1IEP [4].  
 
  
